Gene expression profiling on pre- and post-erlotinib tumors from patients with head and neck squamous cell carcinoma.
BACKGROUND
The purpose of our work was to identify genomic predictive markers of erlotinib response in patients with head and neck squamous cell carcinoma (HNSCC).


METHODS
Tumor tissue biopsies were collected before and after treatment for 39 patients. We analyzed genomic expression of the tumors using microarrays to (1) identify genes differentially expressed in baseline samples in patients who were responders vs nonresponders, (2) characterize erlotinib's effect on gene expression, and (3) identify the pharmacodynamic marker of erlotinib.


RESULTS
Gene expression profiles found no statistically significant differentially expressed genes between responders and nonresponders. An exploratory analysis by combining statistical criteria allowed us to identify genes differentially expressed in nonresponders compared to responders and genes whose expression was modified during erlotinib treatment. Finally, the search of pharmacodynamic markers identified cyclin-dependent kinase 2-interacting protein (CINP) as a potential marker of erlotinib efficacy because its expression decreased only in patients who were responders to the treatment.


CONCLUSIONS
This study provides candidate genes potentially involved in erlotinib response in HNSCC.
EA4553 and Université de Toulouse, 20-24 Rue du Pont St Pierre, 31052 Toulouse, France. thomas.fabienne@claudiusregaud.fr
Fabienne
F
Thomas
Paul
P
Delmar
Sébastien
S
Vergez
Philippe
P
Rochaix
Isabelle
I
Hennebelle
Patricia
P
McLoughlin
Adil
A
Benlyazid
Jérôme
J
Sarini
Jean-Pierre
JP
Delord
D051792:Basic Helix-Loop-Helix Proteins / Q000235:genetics; D015415:Biomarkers / Q000032:analysis; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000235:genetics* / Q000601:surgery; D002352:Carrier Proteins / Q000235:genetics; D000069347:Erlotinib Hydrochloride; D005260:Female; D020869:Gene Expression Profiling; D014453:Glucuronosyltransferase / Q000235:genetics; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000601:surgery; D006801:Humans; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009363:Neoplasm Proteins / Q000235:genetics; D020411:Oligonucleotide Array Sequence Analysis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D000099148:UGT1A1 Enzyme
D051792:Basic Helix-Loop-Helix Proteins; D015415:Biomarkers; D002352:Carrier Proteins; D000069347:Erlotinib Hydrochloride; D014453:Glucuronosyltransferase; D009363:Neoplasm Proteins; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000099148:UGT1A1 Enzyme; C510853:CINP protein, human; C491643:NUPR1 protein, human